Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($0.75), $0.02 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $0.

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.